Blog

Optima Health plc (LSE:OPT) has upgraded its profit outlook, expecting adjusted EBITDA for the year ended 31 March 2026 to come in roughly 10% above market expectations. The improved guidance reflects strong trading in the second half and continued progress toward its medium-term goals of £200 million in revenue and £40 million in adjusted EBITDA.

A key driver of the company’s momentum is its recent acquisition of PAM, which management describes as a transformative move. The deal is set to strengthen Optima Health’s standing in the occupational health sector while delivering operational efficiencies and cost synergies. In addition, the resolution of a prior procurement issue, along with related operating income, has provided further support to financial performance.

Despite the positive trajectory, some challenges remain. The business reported negative free cash flow in 2025, and its valuation remains elevated, with a price-to-earnings ratio around 50 despite relatively thin margins. While profitability has improved and leverage remains modest, earnings volatility continues to weigh on investor confidence. Market indicators are also mixed, with neutral momentum and the share price trading below longer-term averages.

More about Optima Health PLC

Optima Health plc is a UK-based provider of occupational health and wellbeing services, combining clinical expertise with technology-driven solutions. The company supports millions of employees through a network of more than 50 clinics and a workforce exceeding 2,000 staff, including around 1,250 clinicians. Its services are delivered across both public and private sectors in the UK, with additional operations in Ireland.

The group focuses on corporate health and wellbeing, using digital platforms alongside clinical delivery to support employers and employees. Its position in the growing occupational health market is supported by its scale, extensive clinic network, and expanding presence across the UK and Ireland.

Serica Energy (LSE:SQZ) has issued nil-cost share options covering 1,640,464 ordinary shares—around 0.42% of its issued capital—under its 2017 Long Term Incentive Plan to senior executives and management. Of this total, 787,789 shares have been allocated to executive directors, including 523,255 options granted to Chief Executive Officer Christopher Cox and 264,534 to Chief Financial Officer Martin Copeland. The awards are subject to a three-year performance period based on relative total shareholder return (TSR), aligning payouts with shareholder outcomes.

The structure links vesting directly to performance against peers, reinforcing Serica’s focus on incentivising long-term value creation. While the allocation represents a relatively small proportion of the company’s share base—helping to limit dilution—it is designed to provide meaningful retention and motivation for senior leadership.

Looking ahead, Serica’s near-term outlook reflects a mixed picture. Financial performance has come under pressure, with a decline in 2025 revenue, a net loss, and negative free cash flow. However, this is partly balanced by improving technical momentum and a more constructive forward view, including reaffirmed 2026 guidance, a strengthening net debt position, and a maintained dividend. Valuation remains supported by its high yield, though losses continue to weigh on traditional earnings metrics such as the P/E ratio.

More about Serica Energy

Serica Energy plc is a UK-based independent oil and gas company focused on upstream exploration and production activities. Its core operations are located in the UK North Sea, where it develops and produces hydrocarbon resources.

A handbag made from lab grown T Rex leather may sound like science fiction, but it is now a reality. This groundbreaking development could signal a major shift in the future of materials, particularly within the luxury fashion industry.

At the centre of this innovation is BSF Enterprise plc (LSE:BSFA) led by CEO Che Connon and Chairman Geoff Baker. The company has unveiled what is being described as the world’s first handbag made from lab grown T Rex leather, marking a significant milestone in biotech materials.

Redefining Luxury Through Biotechnology

According to Che Connon, this development goes far beyond creating an alternative to traditional leather. While leather remains a multi billion pound global market, it is increasingly under pressure due to environmental concerns, ethical scrutiny, and supply chain instability.

Rather than simply offering a more sustainable version of cowhide, BSF Enterprise plc is aiming to redefine the very foundation of luxury materials. The concept of T Rex leather represents a unique intersection between deep heritage and cutting edge science, placing the company in a distinctive and highly innovative position.

The Technology Behind T Rex Leather

The breakthrough is powered by the company’s Advanced Tissue Engineering Platform, known as ATIP. This technology enables scientists to precisely control the biological environment of cells within sterile bioreactors.

By doing so, the cells are directed to produce their own structure, forming a collagen rich material that is indistinguishable from traditional leather at a cellular level. Remarkably, the process can begin from a single cell, over which the company has full genomic control.

This means the material can be programmed to replicate characteristics of different species, including extinct ones like the T Rex. The resulting collagen may even reflect biological traits associated with prehistoric environments, such as enhanced strength and durability.

Beyond the Headline: Commercial Potential

While the concept of T Rex leather has captured attention, investors are particularly interested in the broader implications of the technology.

The ATIP platform is not limited to one application. It has the potential to produce materials from a wide range of sources, including exotic, endangered, and even extinct species. This opens up new possibilities across multiple industries, with luxury fashion being the most immediate focus.

The company is now working to move beyond proof of concept and into commercialisation, positioning itself at the forefront of a new category of biotech driven luxury.

Entering the Luxury Market

BSF Enterprise plc is strengthening its market strategy with the involvement of UK entrepreneur John Story, a strategic investor with extensive experience in luxury goods, including watches, jewellery, and accessories.

His expertise is expected to play a key role in shaping the company’s go to market approach. Potential applications extend beyond handbags to include watch straps, accessories, and other high end products, where the uniqueness of T Rex leather could command significant premium value.

A Glimpse Into the Future

While the idea of T Rex leather may invite comparisons to science fiction, its real significance lies in what it represents: a shift from natural resource dependence to engineered materials.

Rather than recreating Jurassic Park, this innovation points towards a future where materials are designed at a cellular level, offering greater sustainability, control, and creative freedom.

As BSF Enterprise plc continues to develop its platform, the question is no longer whether lab grown materials will play a role in luxury markets, but how far their impact will reach.

For more information visit – https://bsfenterprise.com/

NewRiver REIT (LSE:NRR) has arranged a new £240 million unsecured financing package, comprising a £120 million term loan and a £120 million revolving credit facility, allowing the company to transition back to a fully unsecured balance sheet while extending the maturity of its debt.

The term loan, set to run until April 2030 with potential extension options, is expected to be drawn nearer to January 2027 to refinance an existing £140 million secured shopping centre loan. By replacing this facility, NewRiver aims to take advantage of its relatively low 3.5% interest rate, generating savings that are expected to support shareholder returns through its dividend policy.

At the same time, the company has expanded its revolving credit facility to £120 million, with a new maturity date of April 2031 and improved pricing compared to the previous arrangement. The increased capacity and lower margin reflect continued lender confidence in the REIT’s investment-grade standing and underlying retail portfolio. With more than £200 million in available cash and liquidity, and all four existing banks increasing their commitments, NewRiver believes it is well positioned to pursue growth opportunities and manage the refinancing of its £300 million unsecured bond due in 2028.

While the company benefits from solid financial performance, favourable valuation metrics, and supportive technical trends, it continues to operate with relatively high leverage and faces ongoing refinancing obligations that could present risks.

More about NewRiver REIT

NewRiver REIT plc is a UK-based real estate investment trust focused on acquiring, managing, and developing retail properties. Following its acquisition of Capital & Regional in December 2024, the group oversees a portfolio valued at approximately £0.8 billion, including 24 community shopping centres and 11 retail parks, primarily occupied by tenants offering essential goods and services. In addition, it manages assets on behalf of partners, bringing total assets under management to around £2.3 billion.

MedPal AI (LSE:MPAL) has completed a £3 million fundraising through the placement of 120 million new shares at 2.5 pence each, representing a 13% discount to the previous closing price. The raise attracted new institutional investors and includes the appointment of OAK Securities as joint broker, aimed at strengthening the company’s institutional reach. Following the transaction, MedPal’s total issued share capital will increase to 612,441,036 shares, with the new shares expected to begin trading on AIM on 22 April 2026.

The company plans to use the proceeds to expand marketing efforts for its MedPal.clinic weight-loss platform, support working capital amid rising NHS dispensing volumes and growth in its care home segment, and fund key senior hires. Investment will also go toward completing robotic capacity at its Runcorn facility. Management believes the funding will accelerate its path toward profitability by supporting the rollout of commercial partnerships and reinforcing its presence in the fast-growing UK markets for GLP-1 treatments and digital healthcare.

More about MedPal AI Plc

MedPal AI Plc is a UK-based digital health and artificial intelligence company focused on its MedPal Health OS platform, which integrates AI-driven wellness tools, clinical services, and automated pharmacy fulfilment. Through its subsidiary MedPal Limited, the group operates a круглосуточный AI-powered robotic pharmacy distribution centre handling NHS and private prescriptions across the UK, alongside a rapidly expanding GLP-1 weight-loss clinic and B2B supply services for care homes.

Quantum Base Holdings (LSE:QUBE) reported accelerating commercial progress, projecting FY26 revenues in the range of £455,000 to £595,000. Growth is being supported by expanded collaboration with a major global security printer and the addition of a global art authentication registry to its client base.

The company noted that several agreements, along with roughly £42,000 in setup-related fees, have been pushed into FY27. This timing shift has contributed to a larger-than-anticipated EBITDA loss for the current year. Despite this, Quantum Base maintains a solid financial position, with £3.4 million in net cash, and is engaged in advanced discussions with prospective clients across multiple industries.

On the operational side, the firm introduced its Q-ID Scanner 2.0 application on iOS, reducing authentication times to under three seconds while improving usability in low-connectivity settings. An Android version is currently under development. Quantum Base has also expanded its sales and marketing capabilities to support increasing demand, as awareness of its Q-ID technology grows across sectors such as security printing, pharmaceuticals, and brand protection.

More about Quantum Base Holdings Plc

Quantum Base Holdings is a UK-based quantum technology company behind Q-ID, a patented authentication system designed to produce unique, non-replicable identifiers to combat counterfeiting. The solution can be embedded into standard printing processes and verified באמצעות smartphones, targeting applications in security printing, pharmaceuticals, brand protection, and other high-value industries.

Caledonia Mining Corporation Plc (LSE:CMCL) has announced a slight change to the payment schedule for its quarterly dividend of US$0.14 per share, affecting holders of depositary interests traded on AIM. The payment date has been moved from April 17, 2026 to April 20, 2026, with no changes to the dividend amount or other associated terms.

This update applies only to investors holding depositary interests on the London AIM market. The broader dividend plan outlined in March 2026 remains fully in place, signaling that the adjustment is purely administrative. There is no indication of any shift in the company’s financial position or dividend strategy, though AIM investors should take note of the revised payment date for cash flow planning.

More about Caledonia Mining

Caledonia Mining Corporation Plc is a gold-focused mining company with listings on the NYSE American, AIM, and the Victoria Falls Stock Exchange under the ticker CMCL. The business is centered on precious metals production, offering investors exposure to the global gold mining industry across multiple international markets.

Fevara plc (LSE:FVA), a London-listed livestock nutrition specialist, has entered into a five-year exclusive distribution agreement with Brazil-based Oceana Minerals to introduce its LithoNutri product to the Great Britain and Ireland markets.

Fevara develops and commercialises science-led nutritional solutions for livestock, including feed licks, mineral blocks, and boluses for cattle, sheep, and horses. Its portfolio includes well-known brands such as Crystalyx and Horslyx, and the company operates from its Carlisle headquarters with manufacturing facilities spanning the UK, United States, and Brazil, alongside joint ventures in Germany and the U.S. Its products are sold in more than 20 countries, with a focus on enhancing efficiency and sustainability in grazing systems.

Under the agreement, LithoNutri—a seaweed-based rumen health and digestion enhancer—will be added to Fevara’s product range. The company plans to utilise its established distribution network and strong customer base to expand adoption, aiming to support improved milk production and livestock growth rates. The addition is also expected to strengthen the market position of Fevara’s core brands, including Crystalyx, Scotmin, Horslyx, and Tracesure, across the UK and Ireland.

The collaboration reflects a model Fevara has successfully implemented in regions such as New Zealand, where partnerships have supported market expansion. Both companies intend to work closely through joint technical development, research initiatives, and commercial efforts to build the GB&I market for LithoNutri. Although the agreement is not considered financially material in regulatory terms, it highlights Fevara’s ongoing strategy of leveraging partnerships and sustainable product innovation to reinforce its role as a research-driven player in livestock nutrition while opening a new European channel for Oceana Minerals.

Looking ahead, Fevara’s outlook is supported by an expected improvement in FY2025 financial performance, including a recovery in profitability, stronger free cash flow, and relatively low leverage. However, this is balanced by past fluctuations in earnings and less consistent cash conversion. Market indicators remain broadly neutral, with the share price trading below longer-term averages, while valuation appears reasonable and supported by dividend returns.

More about Fevara plc

Fevara plc is a global provider of livestock nutritional products, focused on supporting farmers operating in extensive grazing systems with research-based solutions designed to improve productivity, efficiency, and sustainability. The company produces feed licks, mineral supplements, and boluses for cattle, sheep, and horses, marketed under brands such as Crystalyx, Horslyx, Scotmin Nutrition, SmartLic, Tracesure Advanced, and Macal.

Headquartered in Carlisle, UK, Fevara operates six manufacturing facilities across the UK, U.S., and Brazil, supported by joint ventures in Germany and the United States. Listed on the London Stock Exchange since 1972, the company maintains a broad international distribution network and continues to position itself as a key participant in the global livestock nutrition sector, with a strong emphasis on innovation and sustainable farming solutions.